MKLN1 and hepatocellular carcinoma: Next, we measured the effectiveness of MKLN1-AS-knockdown in combination with lenvatinib, an oral molecule multi-kinase inhibitor in patients with unresectable HCC whose antitumor activity has been demonstrated in vitro and in vivo [14,15].